Back to top
more

Integer Holdings (ITGR)

(Real Time Quote from BATS)

$132.48 USD

132.48
9,491

+0.05 (0.04%)

Updated Oct 15, 2024 10:27 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

ITGR vs. EW: Which Stock Is the Better Value Option?

by Zacks Equity Research

ITGR vs. EW: Which Stock Is the Better Value Option?

Why Is Tandem Diabetes Care, Inc. (TNDM) Up 33.2% Since Last Earnings Report?

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Nevro's (NVRO) Latest Buyout to Boost SI Joint Pain Treatment

by Zacks Equity Research

Nevro's (NVRO) latest acquisition is likely to bring long-term pain relief to people suffering from chronic low back pain associated with the SI joint.

Revvity (RVTY) Launches New Molecular Testing for Newborns

by Zacks Equity Research

Revvity's (RVTY) EONIS Q System is set to transform SMA and SCID testing, advancing global healthcare for infants.

Reasons to Add Intuitive Surgical (ISRG) to Your Portfolio Now

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.

Here's Why Investors Should Hold Humana (HUM) Stock for Now

by Zacks Equity Research

Humana (HUM) is expected to benefit from a strong growth outlook, upgraded health plan offering suite, expanding Medicare Advantage membership, and solid cash reserves.

3 Reasons to Retain Inspire Medical (INSP) Stock for Now

by Zacks Equity Research

Inspire Medical's (INSP) focus on R&D raises optimism about the stock.

Inari Medical's (NARI) PEERLESS II RCT to Boost Patient Outcome

by Zacks Equity Research

Inari Medical's (NARI) latest announcement of first patient enrollment in PEERLESS II RCT is likely to aid in changing guidelines in treating intermediate-risk PE patients globally.

Zacks.com featured highlights DaVita, Brinker International, CNA Financial and Integer Holdings

by Zacks Equity Research

DaVita, Brinker International, CNA Financial and Integer Holdings have been highlighted in this Screen of The Week article.

Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

Patterson Companies (PDCO) Q2 Earnings Miss, EPS View Lowered

by Zacks Equity Research

Patterson Companies' (PDCO) second-quarter fiscal 2024 results reflect improvement in Dental Consumable sales, which were offset by lower Dental Equipment sales. Animal health sales improve.

Vasundhara Sawalka headshot

4 Stocks Trading Near 52-Week High That Can Climb Further

by Vasundhara Sawalka

Investors target stocks that have been on a bullish run lately. Stocks like DVA, EAT, CNA and ITGR that are seeing price strength have a high chance of carrying the momentum forward.

Reasons to Retain West Pharmaceutical (WST) in Your Portfolio

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Reasons to Retain The Cooper Companies (COO) in Your Portfolio

by Zacks Equity Research

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.

Here's Why Investors Should Retain Abbott (ABT) Stock Now

by Zacks Equity Research

Investors are optimistic about Abbott (ABT) driven by expansion in the global market and raised guidance.

Haemonetics (HAE) Stock Up 4.2% YTD: Will the Rally Continue?

by Zacks Equity Research

Investors are optimistic about Haemonetics (HAE), driven by a strategic focus on establishing leading positions in high-growth markets and raised guidance.

Cencora (COR) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.

3 Reasons to Retain Ecolab (ECL) Stock in Your Portfolio

by Zacks Equity Research

Ecolab's (ECL) strength in business raises optimism about the stock.

Haemonetics' (HAE) Plasma Growth, Innovation Aid Performance

by Zacks Equity Research

Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.

Here's Why Integer (ITGR) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Reasons to Retain Cencora (COR) Stock in Your Portfolio for Now

by Zacks Equity Research

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Cardinal Health (CAH) Gets FDA Warning for Monoject Syringes

by Zacks Equity Research

The FDA is alerting healthcare providers and facilities against the use of Cardinal Health's (CAH) Monoject syringes with syringe pumps and PCS pumps.

Insulet (PODD) Up 31.5% Since Q3 Earnings: What's Driving It?

by Zacks Equity Research

Insulet (PODD) continues to gain from the strong adoption of Ommipod 5 and market expansion.

Cardinal Health (CAH) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.

Fresenius Medical (FMS) Ups '23 Outlook After Legal Settlement

by Zacks Equity Research

Fresenius Medical (FMS) wins legal dispute against the U.S. government. Both revenues and operating income will benefit from the settlement agreement.